Compare EVTC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | HROW |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | 373 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2013 | N/A |
| Metric | EVTC | HROW |
|---|---|---|
| Price | $26.42 | $43.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $35.80 | ★ $69.86 |
| AVG Volume (30 Days) | 760.3K | ★ 790.1K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $453,869,000.00 | N/A |
| Revenue This Year | $12.68 | $31.62 |
| Revenue Next Year | $6.86 | $50.77 |
| P/E Ratio | $67.08 | ★ N/A |
| Revenue Growth | ★ 11.48 | N/A |
| 52 Week Low | $21.81 | $28.54 |
| 52 Week High | $37.79 | $54.98 |
| Indicator | EVTC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 71.01 |
| Support Level | $25.39 | $40.61 |
| Resistance Level | $30.05 | $51.01 |
| Average True Range (ATR) | 1.21 | 2.11 |
| MACD | 0.30 | 0.96 |
| Stochastic Oscillator | 72.31 | 88.14 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.